The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 2

PMID 34199035

Citations 29

Authors

Aleksandra Hliwa

Bruno Ramos-Molina

Dariusz Laski

Adriana Mika

Tomasz Sledzinski

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a major public health problem worldwide. NAFLD (both simple steatosis and steatohepatitis) is characterized by alterations in hepatic lipid metabolism, which may lead to the development of severe liver complications including cirrhosis and hepatocellular carcinoma. Thus, an exhaustive examination of lipid disorders in the liver of NAFLD patients is much needed. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid alterations in a number of human diseases, including NAFLD. This review summarizes the current research on lipid alterations associated with NAFLD and related complications, with special emphasis on the changes in long-chain and short-chain fatty acids levels in both serum and liver tissue, as well as in the hepatic expression of genes encoding the enzymes catalyzing lipid interconversions.

Citing Articles

Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation.

Meade R, Ibrahim D, Engel C, Belaygorod L, Arif B, Hsu F Commun Biol. 2025; 8(1):262.

PMID: 39972116 PMC: 11840040. DOI: 10.1038/s42003-025-07656-1.

Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats.

Martin-Grau M, Casanova P, Moreno-Morcillo L, Morales J, Marrachelli V, Monleon D Int J Mol Sci. 2025; 26(3).

PMID: 39941056 PMC: 11818068. DOI: 10.3390/ijms26031288.

The effects of saturated and unsaturated fatty acids on MASLD: a Mendelian randomization analysis and in vivo experiment.

Xu F, Albadry M, Doding A, Chen X, Dirsch O, Schulze-Spate U Eur J Nutr. 2024; 64(1):52.

PMID: 39718605 PMC: 11668845. DOI: 10.1007/s00394-024-03560-2.

Higher levels of plasmatic saturated fatty acid were significantly associated with liver fibrosis in HIV mono-infection: A case-control study.

Almeida C, Arantes Ferreira Peres W, Silva P, Santos de Aguiar Cardoso C, de Andrade M, Castro-Alves J Metabol Open. 2024; 24:100334.

PMID: 39717737 PMC: 11664064. DOI: 10.1016/j.metop.2024.100334.

A Comprehensive Analysis of Liver Lipidomics Signature in Adults with Metabolic Dysfunction-Associated Steatohepatitis-A Pilot Study.

Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Theocharidou E, Germanidis G Int J Mol Sci. 2024; 25(23).

PMID: 39684777 PMC: 11642547. DOI: 10.3390/ijms252313067.

References

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Das U . Essential Fatty acids - a review. Curr Pharm Biotechnol. 2006; 7(6):467-82. DOI: 10.2174/138920106779116856. View

Juarez-Hernandez E, Chavez-Tapia N, Uribe M, Barbero-Becerra V . Role of bioactive fatty acids in nonalcoholic fatty liver disease. Nutr J. 2016; 15(1):72. PMC: 4970250. DOI: 10.1186/s12937-016-0191-8. View

den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk T . Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation. Diabetes. 2015; 64(7):2398-408. DOI: 10.2337/db14-1213. View

Bonsembiante L, Targher G, Maffeis C . Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. Eur J Clin Nutr. 2021; 76(1):28-39. DOI: 10.1038/s41430-021-00928-z. View

Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, Valverde A . Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?. Cell Death Dis. 2020; 11(9):802. PMC: 7519685. DOI: 10.1038/s41419-020-03003-w. View

Dunn W, Bailey N, Johnson H . Measuring the metabolome: current analytical technologies. Analyst. 2005; 130(5):606-25. DOI: 10.1039/b418288j. View

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

Mollica M, Raso G, Cavaliere G, Trinchese G, De Filippo C, Aceto S . Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice. Diabetes. 2017; 66(5):1405-1418. DOI: 10.2337/db16-0924. View

10.

Kew M . Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000; 355(9204):591-2. DOI: 10.1016/S0140-6736(99)00219-6. View

11.

Flowers J, Rabaglia M, Schueler K, Flowers M, Lan H, Keller M . Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes. 2007; 56(5):1228-39. DOI: 10.2337/db06-1142. View

12.

Ferraioli G, Soares Monteiro L . Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019; 25(40):6053-6062. PMC: 6824276. DOI: 10.3748/wjg.v25.i40.6053. View

13.

Hara H, Haga S, Aoyama Y, Kiriyama S . Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine. J Nutr. 1999; 129(5):942-8. DOI: 10.1093/jn/129.5.942. View

14.

Fernandez L, Gomez de Cedron M, Ramirez de Molina A . Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front Oncol. 2020; 10:577420. PMC: 7655926. DOI: 10.3389/fonc.2020.577420. View

15.

Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M . Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest. 2005; 115(4):1030-8. PMC: 1062893. DOI: 10.1172/JCI23962. View

16.

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

17.

Zhao Z, Wang Z, Zhou D, Han Y, Ma F, Hu Z . Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. Cell Mol Gastroenterol Hepatol. 2021; 12(3):857-871. PMC: 8346675. DOI: 10.1016/j.jcmgh.2021.05.006. View

18.

Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T . Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007; 20(3):351-8. View

19.

Wang X, Cao Y, Fu Y, Guo G, Zhang X . Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis. 2011; 10:234. PMC: 3254603. DOI: 10.1186/1476-511X-10-234. View

20.

Goedeke L, Bates J, Vatner D, Perry R, Wang T, Ramirez R . Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Hepatology. 2018; 68(6):2197-2211. PMC: 6251774. DOI: 10.1002/hep.30097. View